Literature DB >> 28122977

Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.

Derek J Royer1, Meghan M Carr1, Ana J Chucair-Elliott1, William P Halford2, Daniel J J Carr3,4.   

Abstract

Viral fitness dictates virulence and capacity to evade host immune defenses. Understanding the biological underpinnings of such features is essential for rational vaccine development. We have previously shown that the live-attenuated herpes simplex virus 1 (HSV-1) mutant lacking the nuclear localization signal (NLS) on the ICP0 gene (0ΔNLS) is sensitive to inhibition by interferon beta (IFN-β) in vitro and functions as a highly efficacious experimental vaccine. Here, we characterize the host immune response and in vivo pathogenesis of HSV-1 0ΔNLS relative to its fully virulent parental strain in C57BL/6 mice. Additionally, we explore the role of type 1 interferon (IFN-α/β) signaling on virulence and immunogenicity of HSV-1 0ΔNLS and uncover a probable sex bias in the induction of IFN-α/β in the cornea during HSV-1 infection. Our data show that HSV-1 0ΔNLS lacks neurovirulence even in highly immunocompromised mice lacking the IFN-α/β receptor. These studies support the translational viability of the HSV-1 0ΔNLS vaccine strain by demonstrating that, while it is comparable to a virulent parental strain in terms of immunogenicity, HSV-1 0ΔNLS does not induce significant tissue pathology.IMPORTANCE HSV-1 is a common human pathogen associated with a variety of clinical presentations ranging in severity from periodic "cold sores" to lethal encephalitis. Despite the consistent failures of HSV subunit vaccines in clinical trials spanning the past 28 years, opposition to live-attenuated HSV vaccines predicated on unfounded safety concerns currently limits their widespread acceptance. Here, we demonstrate that a live-attenuated HSV-1 vaccine has great translational potential.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  HSV-1; T cells; antibody; cornea; mouse; neovascularization

Mesh:

Substances:

Year:  2017        PMID: 28122977      PMCID: PMC5355590          DOI: 10.1128/JVI.02342-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  86 in total

1.  Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants.

Authors:  J P Katz; E T Bodin; D M Coen
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

Review 2.  The latency associated transcripts (LAT) of herpes simplex virus: still no end in sight.

Authors:  T M Block; J M Hill
Journal:  J Neurovirol       Date:  1997-10       Impact factor: 2.643

Review 3.  The virome in mammalian physiology and disease.

Authors:  Herbert W Virgin
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

4.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

5.  The Current State of Vaccine Development for Ocular HSV-1 Infection.

Authors:  D J Royer; A Cohen; Djj Carr
Journal:  Expert Rev Ophthalmol       Date:  2015-04-01

Review 6.  Accelerating next-generation vaccine development for global disease prevention.

Authors:  Wayne C Koff; Dennis R Burton; Philip R Johnson; Bruce D Walker; Charles R King; Gary J Nabel; Rafi Ahmed; Maharaj K Bhan; Stanley A Plotkin
Journal:  Science       Date:  2013-05-31       Impact factor: 47.728

7.  Therapeutic Use of Soluble Fas Ligand Ameliorates Acute and Recurrent Herpetic Stromal Keratitis in Mice.

Authors:  Megan Rogge; Xiao-Tang Yin; Lisa Godfrey; Priya Lakireddy; Chloe A Potter; Chelsea R Del Rosso; Patrick M Stuart
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

8.  Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Authors:  Christopher S Morello; Kimberly A Kraynyak; Michael S Levinson; Zhijiang Chen; Kuo-Fen Lee; Deborah H Spector
Journal:  Vaccine       Date:  2012-09-01       Impact factor: 3.641

Review 9.  Harnessing the beneficial heterologous effects of vaccination.

Authors:  Helen S Goodridge; S Sohail Ahmed; Nigel Curtis; Tobias R Kollmann; Ofer Levy; Mihai G Netea; Andrew J Pollard; Reinout van Crevel; Christopher B Wilson
Journal:  Nat Rev Immunol       Date:  2016-05-09       Impact factor: 53.106

10.  Access of protective antiviral antibody to neuronal tissues requires CD4 T-cell help.

Authors:  Norifumi Iijima; Akiko Iwasaki
Journal:  Nature       Date:  2016-05-18       Impact factor: 49.962

View more
  9 in total

1.  Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"

Authors:  Derek J Royer; Daniel J J Carr
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

2.  Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins.

Authors:  Daniel J J Carr; Grzegorz B Gmyrek; Adrian Filiberti; Amanda N Berube; William P Browne; Brett M Gudgel; Virginie H Sjoelund
Journal:  Immunohorizons       Date:  2020-10-09

3.  The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.

Authors:  Derek J Royer; Meghan M Carr; Hem R Gurung; William P Halford; Daniel J J Carr
Journal:  J Immunol       Date:  2017-07-31       Impact factor: 5.422

4.  Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.

Authors:  Grzegorz B Gmyrek; Adrian Filiberti; Micaela Montgomery; Alisha Chitrakar; Derek J Royer; Daniel J J Carr
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

5.  Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0ΔNLS vaccine against ocular HSV-1 challenge.

Authors:  Daniel J J Carr; Amanda N Berube; Adrian Filiberti; Grzegorz B Gmyrek
Journal:  Vaccine       Date:  2021-04-01       Impact factor: 3.641

6.  Noncognate Signals Drive Enhanced Effector CD8+ T Cell Responses through an IFNAR1-Dependent Pathway after Infection with the Prototypic Vaccine, 0ΔNLS, against Herpes Simplex Virus 1.

Authors:  Grzegorz B Gmyrek; Paul Predki; Edward Gershburg; Daniel J J Carr
Journal:  J Virol       Date:  2022-01-19       Impact factor: 6.549

7.  Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection.

Authors:  Derek J Royer; Joshua F Hendrix; Chelsea M Larabee; Alaina M Reagan; Virginie H Sjoelund; Danielle M Robertson; Daniel J J Carr
Journal:  Mucosal Immunol       Date:  2019-01-22       Impact factor: 7.313

Review 8.  Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back.

Authors:  Aziz A Chentoufi; Nisha R Dhanushkodi; Ruchi Srivastava; Swayam Prakash; Pierre-Gregoire A Coulon; Latifa Zayou; Hawa Vahed; Hiba A Chentoufi; Kathy K Hormi-Carver; Lbachir BenMohamed
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

9.  HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition.

Authors:  Grzegorz B Gmyrek; Amanda N Berube; Virginie H Sjoelund; Daniel J J Carr
Journal:  Sci Rep       Date:  2022-09-23       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.